Many Immune Checkpoint Inhibitor Combination Therapies Show No Evidence of Drug Synergy
The efficacy of many combination therapies may be due to independent drug action, not synergistic or additive effects.
Head and Neck Cancer
HEAD AND NECK CANCER ADVISOR
FEATURED CONTENT
-
-
PTSD in Cancer Patients: What Providers Need to Know
Experts outline risk factors for PTSD and explain how PTSD can affect cancer outcomes. -
How to Prevent a Cyberattack from Derailing Cancer Care
Cyberattacks on health care organizations may not be fully preventable, but there are ways to limit their impact on cancer care. -
New Therapies on the Horizon for Elderly or Frail Patients With Head and Neck Cancer
A nanoparticle-radiotherapy regimen and a chemoimmunotherapy regimen both appear safe and effective for this population. -
Blood-Based Test May Establish a ‘New Paradigm’ for Cancer Screening
The test can accurately detect cancer and predict where it is located, according to researchers.
HEAD AND NECK CANCER NEWS
Proton Beam Therapy Increasingly Used to Treat Cancers, Even When Evidence of Effectiveness Is Lacking
Risk of Neurologic AEs Lower With Immune Checkpoint Inhibitors Than With Other Cancer Therapies
High Neutrophil-Lymphocyte Ratio Linked to Worse Survival in Head and Neck Cancer
Polygenic Risk Score May Identify Patients at High Risk of Nasopharyngeal Carcinoma
Tislelizumab Improves Outcomes in Recurrent, Metastatic Nasopharyngeal Cancer
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Head and Neck Cancer
Loading... 
Loading...